« Return to News | R&D Trends

Broad Institute joins Illumina Genome Network

Thursday, February 16, 2012 06:22 AM

The Broad Institute has joined the Illumina Genome Network (IGN) to offer its proprietary sample preparation processes for whole human genome sequencing.

Broad’s approach enables high-quality sequencing of challenging low input DNA (

There are millions of biological samples within the global research community, most of them largely inaccessible by standard sample prep approaches because they are embedded in paraffin blocks or of very low genomic representation. The new offering through IGN and Broad allows researchers to interrogate these valuable samples that had previously been unable to be sequenced, with the objective to accelerate discovery in critical fields such as oncology.

“Partnering with Illumina allows us to extend our mission by providing researchers worldwide with our capability of processing low input and FFPE samples that are essential to their research,” said Robert Nicol, Ph.D., director of operations and technology development in the genome sequencing platform at the Broad Institute.

Suitability of projects for these specialized services will be evaluated jointly by Broad and Illumina. Interested researchers should contact Illumina directly.

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.